FORT WORTH, Texas, Sept. 27, 2011 /PRNewswire/ -- Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader in advanced wound care solutions, today announced that its President, Deborah Hutchinson will be presenting at AdvaMed 2011: The MedTech Conference. The presentation is scheduled for Wednesday, September 28, 2011 at 9:10 in Room 204A of the Walter E. Washington Convention Center in Washington, D.C. Ms. Hutchinson's presentation will cover the 2011 results and offer the attendees insight into the growth opportunities for the Company's products both domestically and internationally.
AdvaMed 2011 brings the biggest names together to discuss the hottest topic in the MedTech industry. This year's conference plenary speakers include:
Wound Management Technologies has developed a strong schedule for the three-day conference. Scheduled meetings have been arranged with several dozen potential marketing firms, investment groups, distribution partners, and commercialization groups specializing in both national and international markets. The goal of these meetings is to develop strategic partnerships to increase the knowledge and sales of CellerateRX and to assist in research and development of new product initiatives.
"We are honored to present the Wound Management story at an event that features such notable dignitaries as President Bush, Secretary Sebelius and Governors Daniels and O'Malley, among others. AdvaMed 2011 is a great opportunity for Wound Management to showcase its advanced wound care solutions to an audience of thought leaders from both industry and finance and to report on the substantial progress being made," stated Hutchinson. Also joining the meetings will be Cathy Bradshaw of WNDM subsidiary, Wound Care Innovations to participate in discussions on the company's patented collagen product, CellerateRX®
AdvaMed 2011: The MedTech Conference runs September 26-28, 2011. For more information, visit www.AdvaMed2011.com.
About AdvaMed 2011
AdvaMed 2011 is one of the premier MedTech conferences for business leaders, entrepreneurs, policy-makers, media, financiers, and other industry stakeholders from around the world. AdvaMed 2010 attracted 1,700 industry leaders – including many CEOs, Presidents and C-level executives. AdvaMed 2011 is designed to be a perfect event for networking; conducting partnering meetings; influencing policy makers and the media; and participating in educational sessions. For its attendees, AdvaMed 2011 can provide an introduction to many key decision-makers in the industry. For more information, visit www.AdvaMed2011.com.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com and http://www.celleraterx.com.
Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com.
For Further Information:
Shareholder Relations-Communications (917) 974-9872
|SOURCE Wound Management Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved